TriangleNCT00470093 · OUTCOME
Impact of Treatment on Growth of Myeloma Cells
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Day 0, Day 14, Months 1, 2, 4, and 6 of combined therapy, and end of study
What was measured
Percentage change in growth of in vitro myeloma cells from baseline to end of study.
Analysis population: Zero participants tolerated protocol therapy and the research sample blood draws were therefore not completed as planned. Because of this, the data from this outcome could not be collected.
Groups in this outcome
Interleukin-6 and Interferon-α
Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day. recombinant interferon-α recombinant interleukin-6
| Group | Source count |
|---|---|
| Interleukin-6 and Interferon-α | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Percentage change in growth of in vitro myeloma cells from baseline to end of study.
- groups
- description
- Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day. recombinant interferon-α recombinant interleukin-6
- id
- OG000
- title
- Interleukin-6 and Interferon-α
- population Description
- Zero participants tolerated protocol therapy and the research sample blood draws were therefore not completed as planned. Because of this, the data from this outcome could not be collected.
- reporting Status
- POSTED
- time Frame
- Day 0, Day 14, Months 1, 2, 4, and 6 of combined therapy, and end of study
- title
- Impact of Treatment on Growth of Myeloma Cells
- type
- PRIMARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice